Market Research Logo

Celgene Corporation - Product Pipeline Review - 2016

Celgene Corporation - Product Pipeline Review - 2016

Summary



Global Markets Direct’s, ‘Celgene Corporation - Product Pipeline Review - 2016’, provides an overview of the Celgene Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Celgene Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Celgene Corporation
  • The report provides overview of Celgene Corporation including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Celgene Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Celgene Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
  • Evaluate Celgene Corporation’s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Celgene Corporation
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Celgene Corporation’s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Celgene Corporation Snapshot
Celgene Corporation Overview
Key Information
Key Facts
Celgene Corporation - Research and Development Overview
Key Therapeutic Areas
Celgene Corporation - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Pipeline Products - Out-Licensed Products
Celgene Corporation - Pipeline Products Glance
Celgene Corporation - Late Stage Pipeline Products
Celgene Corporation - Clinical Stage Pipeline Products
Celgene Corporation - Early Stage Pipeline Products
Celgene Corporation - Drug Profiles
apremilast
lenalidomide
azacitidine
CC-90007
mongersen
paclitaxel albumin bound
pomalidomide
romidepsin
amrubicin hydrochloride
CC-11050
CC-220
GI-6207
GI-6301
PDA-002
spebrutinib besylate
Stem Cell Therapy for Hematological Malignancies, Non-Malignant Disorders and Hypoxic-ischemic Encephalopathy
CC-122
CC-223
PNK-007
CC-115
CC-90001
CC-90002
CC-90003
CC-90005
Cellular Immunotherapy to Target GD2 for Neuroblastoma
CTP-730
pinometostat
AVL-181
AVL-192
CC-0730671
CC-2142
CC-509
CC-539
Monoclonal Antibody 1 for Inflammation
Monoclonal Antibody 2 for Inflammation
Small Molecules for Undisclosed Indication
Small Molecules to Agonize ROR gamma for Breast Cancer
Antibody for Oncology
Antibody for Undisclosed Indication
CC-0739623
CC-2141
CC-90006
CC-90008
CC-90009
CC-90010
CC-90011
CSC-1
Drug for Hematological Disorders and Oncology
Drug to Inhibit Kinase for Inflammation
Drugs for Hematology and Oncology
Monoclonal Antibody Conjugate to Inhibit Protein S100-A9 for MDS
Small Molecule to Inhibit Brutons Tyrosine Kinase for Inflammation
Small Molecules for Inflammation
Small Molecules for Inflammation and Cancer
Small Molecules for Malaria
Celgene Corporation - Pipeline Analysis
Celgene Corporation - Pipeline Products by Target
Celgene Corporation - Pipeline Products by Route of Administration
Celgene Corporation - Pipeline Products by Molecule Type
Celgene Corporation - Pipeline Products by Mechanism of Action
Celgene Corporation - Recent Pipeline Updates
Celgene Corporation - Dormant Projects
Celgene Corporation - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Celgene Corporation - Company Statement
Celgene Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Celgene Corporation, Key Information
Celgene Corporation, Key Facts
Celgene Corporation - Pipeline by Indication, 2016
Celgene Corporation - Pipeline by Stage of Development, 2016
Celgene Corporation - Monotherapy Products in Pipeline, 2016
Celgene Corporation - Partnered Products in Pipeline, 2016
Celgene Corporation - Partnered Products/ Combination Treatment Modalities, 2016
Celgene Corporation - Out-Licensed Products in Pipeline, 2016
Celgene Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016
Celgene Corporation - Pre-Registration, 2016
Celgene Corporation - Phase III, 2016
Celgene Corporation - Phase II, 2016
Celgene Corporation - Phase I, 2016
Celgene Corporation - Preclinical, 2016
Celgene Corporation - Discovery, 2016
Celgene Corporation - Pipeline by Target, 2016
Celgene Corporation - Pipeline by Route of Administration, 2016
Celgene Corporation - Pipeline by Molecule Type, 2016
Celgene Corporation - Pipeline Products by Mechanism of Action, 2016
Celgene Corporation - Recent Pipeline Updates, 2016
Celgene Corporation - Dormant Developmental Projects,2016
Celgene Corporation - Discontinued Pipeline Products, 2016
Celgene Corporation, Other Locations
Celgene Corporation, Subsidiaries
List of Figures
Celgene Corporation - Pipeline by Top 10 Indication, 2016
Celgene Corporation - Pipeline by Stage of Development, 2016
Celgene Corporation - Monotherapy Products in Pipeline, 2016
Celgene Corporation - Partnered Products in Pipeline, 2016
Celgene Corporation - Out-Licensed Products in Pipeline, 2016
Celgene Corporation - Pipeline by Top 10 Target, 2016
Celgene Corporation - Pipeline by Route of Administration, 2016
Celgene Corporation - Pipeline by Molecule Type, 2016
Celgene Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report